Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02019602 · ClinicalTrials.gov registry record · Phase 1
A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta
A Phase 1 study, sponsored by UCB Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT02019602: Completed Phase 1 study, sponsored by UCB Biosciences.
NCT02019602 is a Phase 1 study that has completed, run by UCB Biosciences. The registered enrollment target is 37 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02019602, a Phase 1 study, has completed, sponsored by UCB Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of infants at birth.
Primary Outcome
Blood samples will be taken within 24 hours after birth from the infant(s).
Interventions
- BIOLOGICAL Certolizumab Pegol
- PROCEDURE Blood sampling from mother
- PROCEDURE Blood sampling from infant
- PROCEDURE Blood sampling from umbilical cord
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-11 |
| Phase | Phase 1 |
What the finished NCT02019602 record still lists
NCT02019602 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (38% lower).
The record links to 0 conditions, and to 4 interventions - of which Certolizumab Pegol is the first listed.
NCT02019602 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02019602 about?
NCT02019602 is a clinical study titled "A Multicener, Postmarketing Study Evaluating the Transfer of Cimzia From the Mother to the Infant Via the Placenta". The primary purpose is to assess whether there is transfer of Certolizumab Pegol (CZP) from pregnant women receiving treatment with Cimzia® across the placenta to infants by evaluating the concentration of CZP in the plasma of infants at birth.
What is the current status of trial NCT02019602?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2014-01. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02019602?
The interventions under investigation include: Certolizumab Pegol (BIOLOGICAL), Blood sampling from mother (PROCEDURE), Blood sampling from infant (PROCEDURE), Blood sampling from umbilical cord (PROCEDURE).
Who is sponsoring clinical trial NCT02019602?
This trial is sponsored by UCB Biosciences, which has 39 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02019602's enrollment target sits among peer trials
37 1204th of 2000 higher than 791 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia